The orphan drug designation is a result of positive findings from a phase 2 clinical trial which demonstrated a 100% clinical benefit rate in patients.
/PRNewswire/ Biostar Pharma, Inc., the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company.